Related Experiment Video
Updated: May 4, 2026
Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma
Published on: January 25, 2015
Primary hepatic angiosarcoma and potential treatment options.
Ya-Wen Zheng1, Xin-Wei Zhang, Jia-Li Zhang
1Department of Biotherapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China; Key Laboratory of Cancer Immunology and Biotherapy, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China; National Clinical Research Center of Cancer, Tianjin, China.
Primary hepatic angiosarcomas (PHAs) are rare, aggressive liver cancers. Optimal treatment involves local excision, potentially with adjuvant therapy, offering a median survival of 17 months.
Area of Science:
- Oncology
- Hepatology
- Pathology
Background:
- Primary hepatic angiosarcomas (PHAs) are rare malignant tumors originating in the liver.
- PHAs constitute a small fraction of soft tissue sarcomas, presenting a poor prognosis.
- Etiology is often unknown, though vinyl chloride exposure is a known risk factor.
Purpose of the Study:
- To review and analyze the clinical characteristics and outcomes of primary hepatic angiosarcomas.
- To identify prognostic factors and optimal management strategies for PHAs.
Main Methods:
- A systematic review of 25 articles published between January 2000 and December 2012.
- Inclusion of 64 cases of PHA with detailed clinical information.
- Survival analysis using the Kaplan-Meier method with SPSS 21.0.
Main Results:
- The median survival time for PHAs is 5 months.
- Local excision, with or without adjuvant therapy, yielded a median survival of 17 months.
- Liver transplantation showed high recurrence rates; transcatheter arterial embolization is effective for bleeding control; chemoembolization and chemotherapy may improve survival.
Conclusions:
- Local excision is the preferred surgical approach for PHAs.
- Adjuvant therapies, chemoembolization, and chemotherapy may enhance survival outcomes.
- Liver transplantation is not recommended due to high recurrence rates.
